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A combination of traditional medicine and modern 
chemistry has provided a promising new lead in the search 
for new antimalarials. Using a rational chemical approach, 
Herman and colleagues (1) have identified the target of 
febrifugine, the active component in the ancient traditional 
medicine changshan, and modified the compound such that 
its side-effects are greatly reduced while the anti-malarial 
activity is maintained. 
Malaria remains an important health concern world-
wide, despite significant advances in the fight against 
this disease. Malaria is caused by parasites of the genus 
Plasmodium, of which Plasmodium falciparum causes the most 
severe disease and nearly all of the fatalities in humans. 
Parasites are introduced into a host by a mosquito bite, 
after which they infect the liver. Following replication in 
the liver, parasites capable of infecting erythrocytes are 
released—it is this stage of the life cycle that is responsible 
for the disease symptoms. A subset of the erythrocytic 
parasites will convert to gametocytes, which can spread the 
disease after being taken up by a mosquito during a blood 
meal. Over the past 15 years, the reported toll of malaria has 
decreased 60% to ~438,000 lives lost per annum, according 
to the most recent WHO report (2). This decrease is 
in no small part the result of the widespread use of the 
antimalarial drug artemisinin (and derivatives thereof), used 
in combination with a second antimalarial. However, these 
gains are now under threat by the emergence of parasites 
resistant against artemisinin (3). Hence, development of 
new antimalarial drugs is of great importance. 
Traditional medicine has been a source of many 
drugs, including antimalarials. Famously, the antimalarial 
compounds quinine and artemisinin are derived from 
bark of the Cinchona tree and the Artemisia annua tree, 
respectively. Tu Youyou, the discoverer of artemisinin, 
was awarded the Nobel Prize in Physiology or Medicine 
in 2015 for her important work on artemisinin. Less well 
known is changshan, an extract of the herb Dichroa febrifuga, 
which was used already 2,000 years ago to treat the fevers 
induced by malaria (4). The active ingredient in changshan, 
febrifigune, was extracted in the 1940’s (5,6). Although 
effective against malaria, the severe side effects (including 
nausea and vomiting) of changshan and purified febrifugine 
have prevented their development as an antimalarial (4,7). 
Several attempts have been made in the past to decrease 
the side effects through chemical modification, but none 
of them have been successful (7). Now Herman and 
colleagues describe two major advances in the development 
of derivatives of febrifugine as anti-malarial compounds: the 
identification of its target in the parasite and a modification 
of the compound that greatly decreases the side effects. 
To discover the target of febrifugine, Herman and 
colleagues cultured P. falciparum parasites in the presence 
of halofuginone, a derivative of febrifugine, until resistant 
parasites arose. Whole genome sequencing of two 
independent clones revealed two different mutations in 
the same codon of the gene that encodes the cytoplasmic 
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prolyl-tRNA synthetase. This enzyme charges tRNA(Pro) 
with proline and hence is essential for protein synthesis. To 
verify that this enzyme is the direct target of halofuginone 
the authors took advantage of the finding that the yeast 
Saccharomyces cerevisiae is not sensitive to halofuginone. They 
constructed S. cerevisiae strains in which the only functional 
prolyl-tRNA synthetase was either the S. cerevisiae enzyme, 
the wildtype P. falciparum enzyme or the halofuginone-
resistant P. falciparum enzyme. Consistent with the enzyme 
being the target of halofuginone, only parasites carrying 
the S. cerevisiae or the halofuginone-resistant P. falciparum 
enzyme, but not the wildtype P. falciparum enzyme, grew in 
the presence of the drug. The authors further showed that 
halofuginone treatment of P. falciparum induces an amino 
acid starvation response in the parasite, further linking 
halofuginone with the process of protein synthesis.
Important for the development of any drug is an 
understanding of the binding of the compound to its 
target at a molecular level. Modeling of the interaction of 
halofuginone with the prolyl-tRNA synthetases from S. 
cerevisiae and P. falciparum, structures of which have recently 
been solved (8,9), revealed a potential molecular mechanism 
of the binding of the drug to its target, and insight into why 
the drug only inhibits the P. falciparum enzyme but not the 
yeast enzyme.
Many derivatives of febrifugine have been synthesized 
over the years, including more active compounds, such 
as halofuginone (10). However, active derivatives still 
produced the same side effects as febrifugine (7). Analyzing 
the chemical structures of halofuginone and febrifugine, 
the authors reasoned that a central ketone functional 
group could act as a reactive group, leading to side effects 
that are independent of its activity against the prolyl-
tRNA synthetase enzyme. As previous work had shown 
that derivations lacking this ketone are inactive (11), 
the authors replaced the ketone with a secondary alcohol, 
thereby maintaining the ability of this part of the 
compound to interact with the prolyl-tRNA synthetase. 
This new molecule, named halofuginol, had a very similar 
in vitro activity against blood stage P. falciparum compared 
to febrifugine, with EC50 values of 5.8 and 4.0 nM, 
respectively. In addition, halofuginol also killed liver stage 
parasites of the model rodent malaria parasite Plasmodium 
berghei in vitro. When the authors next used the P. berghei 
model to investigate the efficacy of the compound in vivo, 
they found that the parasitemia in P. berghei-infected mice 
treated with halofuginol, either orally or intraperitoneally, 
was >99% lower than in control animals. Importantly, at the 
dose used, 25 mg/kg, none of the side effects of febrifugine 
were detected, indicating that the chemical modification 
had successfully removed the off-target effects while 
maintaining the anti-malarial activity. With this, the authors 
showed that halofuginol is active against asexual blood stage 
and liver stage parasites similar to fubrifigone, without the 
side effects. 
The combination of traditional medicine and modern 
chemistry has thus provided a very promising new starting 
point for the development of a novel anti-malarial. As 
the authors point out, much remains to be done, such 
as further investigation of the pharmacokinetics and the 
development of derivatives with a lower affinity for the 
human orthologue of prolyl-tRNA synthetase. Also, efficacy 
against gametocytes needs to be tested. Efficacy against this 
stage of the parasite lifecycle is considered an important 
aspect of any new anti-malarial drug, as it would prevent 
host-to-host transmission of the disease. However, despite 
these outstanding questions, the anti-malarial drug pipeline 
will always welcome a new compound. 
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